Literature DB >> 1703149

Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide.

I F Charo1, L Nannizzi, D R Phillips, M A Hsu, R M Scarborough.   

Abstract

The glycoprotein IIb-IIIa complex (GP IIb-IIIa) mediates platelet aggregation and is a member of the cytoadhesin family of receptors that bind adhesive proteins such as fibrinogen, fibronectin, and von Willebrand factor. Despite the wide range of cell-substrate interactions mediated by these receptors, ligand binding domains have not yet been identified on any of the integrins. The present study was designed to determine potential fibrinogen binding domain(s) on the GP IIb-IIIa complex. Synthetic peptides derived from residues 1-288 of the amino-terminal portion of GP IIIa were tested for their abilities to block the binding of fibrinogen to purified GP IIb-IIIa in a solid-phase microtiter assay. Two overlapping peptides encompassing residues 204-229 of GP IIIa were identified which blocked fibrinogen binding in this assay. Polyclonal antibodies to these peptides blocked fibrinogen binding to purified GP IIb-IIIa as well as platelet aggregation. The overlapping residues of these two peptides GP IIIa (211-222), SVSRNRDAPEGG-NH2, blocked the binding of fibronectin, von Willebrand factor, and vitronectin to purified GP IIb-IIIa. Finally, direct binding of GP IIIa (204-229) to fibrinogen and fibronectin was demonstrated by enzyme-linked immunosorbent assay. We conclude from these studies that the amino acid sequence 211-222 of GP IIIa is critically involved in adhesive protein binding, and may represent an important portion of the GP IIb-IIIa ligand binding domain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703149

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.

Authors:  J C O'Shea; J E Tcheng
Journal:  J Thromb Thrombolysis       Date:  2000-12       Impact factor: 2.300

2.  Advantages of RGD peptides for directing cell association with biomaterials.

Authors:  Susan L Bellis
Journal:  Biomaterials       Date:  2011-06       Impact factor: 12.479

3.  Proteolytic dissection of the isolated platelet fibrinogen receptor, integrin GPIIb/IIIa. Localization of GPIIb and GPIIIa sequences putatively involved in the subunit interface and in intrasubunit and intrachain contacts.

Authors:  J J Calvete; K Mann; M V Alvarez; M M López; J González-Rodríguez
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

4.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Streptococcal pyrogenic exotoxin B-induced apoptosis in A549 cells is mediated through alpha(v)beta(3) integrin and Fas.

Authors:  Wan-Hua Tsai; Chia-Wen Chang; Yee-Shin Lin; Woei-Jer Chuang; Jiunn-Jong Wu; Ching-Chuan Liu; Pei-Jane Tsai; Ming T Lin
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

6.  An echistatin C-terminal peptide activates GPIIbIIIa binding to fibrinogen, fibronectin, vitronectin and collagen type I and type IV.

Authors:  P S Wright; V Saudek; T J Owen; S L Harbeson; A J Bitonti
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

7.  The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms.

Authors:  J M Bergelson; B M Chan; R W Finberg; M E Hemler
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Modeling the alpha IIb beta 3 integrin solution conformation.

Authors:  M Rocco; B Spotorno; R R Hantgan
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

Review 9.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  A new alternative transcript encodes a 60 kDa truncated form of integrin beta 3.

Authors:  I Djaffar; Y P Chen; C Creminon; J Maclouf; A M Cieutat; O Gayet; J P Rosa
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.